#USA #Boca Raton #radiopharmaceuticals #PharmaLogic #Etienne Montagut

PharmaLogic Elevates Etienne Montagut to CEO

PharmaLogic Holdings Corp. has formally announced the promotion of Etienne Montagut to the role of President and Chief Executive Officer (CEO), effective from June 1, 2025. This decision marks a significant shift in the leadership framework of the Company, which is recognized as a leader in contract development and manufacturing specifically for radiopharmaceuticals.

Montagut, who previously served as the Company’s President, brings with him over 25 years of rich, diverse experience within the pharmaceutical sector. His career includes leadership roles at notable companies, such as Lantheus, GE HealthCare, and Ipsen. These positions have equipped him with the skills needed to drive growth and implement strategic transformations across various global markets, establishing him as a prominent figure in the industry.

The transition comes as the former CEO, Steve Chilinski, retired after 13 remarkable years during which he guided PharmaLogic through substantial growth. As part of this reshuffle, Chilinski will now take on the role of Executive Chairman of the Board, continuing to shape the Company’s direction.

"I am extremely grateful to Steve and our Board for their trust and confidence in the future of PharmaLogic," Montagut stated in a press release. "The company has achieved significant success, and I am highly motivated about the next chapter. We possess the talent, culture, technology, and resources to lead the future of radiopharmaceuticals and improve global patient access to innovative diagnostics and therapies."

About PharmaLogic Holdings Corp.

PharmaLogic prides itself on being a distinguished global contract development and manufacturing organization (CDMO) that specializes in the production and distribution of diagnostic and therapeutic radiopharmaceuticals. With an operational network that spans over 45 facilities located in the U.S., Puerto Rico, Canada, and Norway, PharmaLogic is committed to maintaining the highest standards of quality and regulatory compliance in the industry.

The Company’s diagnostics division is rapidly evolving, leveraging advanced technologies to broaden patient access to cutting-edge diagnostics across various fields, including oncology, cardiology, and Alzheimer’s disease. Moreover, PharmaLogic is notable for being the only cGMP-compliant CDMO that manufactures and distributes a commercial radiopharmaceutical therapeutic in over 30 countries worldwide.

PharmaLogic is committed to enhancing global patient access to radiopharmaceuticals. This commitment is exemplified through strategic partnerships with industry innovators, advancing the trajectory of the field, and providing continuous support to partners throughout the product lifecycle.

To learn more about PharmaLogic’s offerings and innovative initiatives, visit radiopharmacy.com or connect with them on LinkedIn.

With Montagut’s extensive experience and proven leadership, the Company is well-positioned to navigate the challenges and opportunities in the evolving landscape of radiopharmaceuticals, ensuring a brighter future for patients worldwide.